The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
You are here: Home / Antibody discovery / Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases

Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases

September 26, 2017 by The Antibody Society

The Antibody Society is pleased to invite you to attend its annual Meeting, Antibody Engineering & Therapeutics, which will be held December 11-15, 2017, in San Diego, CA. We will be celebrating the 10th anniversary of the Society at the Society’s Special Session on Thursday December 14, 2017.  In session previews that will be posted during September-November, the session chairs discuss the relevance of their topics to current and future antibody therapeutics development.

The nervous system is especially vulnerable to the disrupted proteostasis and accumulations of toxic forms of proteins that occur naturally with aging, and/or as a result of genetic and environmental risk factors. As our overall populations age, these disorders loom as a massive public health problem due to the level of care required for affected individuals. Antibodies, with their inherent specificity for protein isoforms, will become increasingly critical as therapeutics and diagnostics. Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases, which will be presented on Wed. morning, Dec. 13, has been organized by Anne Messer (Neural Stem Cell Institute/ Univ. Albany), Cynthia Lemere (Brigham & Women’s Hospital/Harvard Medical School) and James Huston (Huston BioConsulting, LLC). The speakers in this session will present a range of approaches for Alzheimer’s and related dementias, Parkinson’s, and ALS/motor neuron disease, including notes on the extent to which there can be overlaps among these and other protein misfolding diseases.

The talks in the first half of the session will focus on an important target in Alzheimer’s, amyloid beta (Aβ). Isabelle Aubert (University of Toronto) will present the opening talk, “Delivery of Antibodies across the Blood-brain Barrier Using MRI-guided Focused Ultrasound,” including promising data on functional improvement after treatments with anti- Aβ antibodies. [This talk also represents a continuation of the theme of approaches to blood brain barrier permeability in the keynote talk by William Pardridge (UCLA), and a session talk by Jasi Atwal (Genentech), on Tuesday, Dec. 13.] Next in our session, Christoph Hock (University of Zurich) will present “Antibody Therapy for Alzheimer’s Disease – Key Challenges.” These challenges include targeting the most relevant Aβ species, establishing a consistent dose-response, selecting the right timing and duration of the intervention, demonstrating a clinical / biomarker correlation and managing amyloid related imaging abnormalities (ARIA E/H). 
Michael Sierks (Arizona State University) will present his cutting-edge engineering and catalytic antibody approaches to preventing formation of the toxic species in “Altering APP Processing with a Proteolytic Diabody.”

The second half of the session covers immunotherapies for multi-faceted neurodegenerations. 
Laura Ranum (University of Florida) uses a mouse model of a human mutation that can lead to motor, cognitive, and/or anxiety symptoms due to accumulation of novel mutant proteins. These may be less rare than we currently appreciate. In the talk “Towards Development of Antibody Therapy for C9orf72 ALS/FTD”, Prof. Ranum will present preclinical studies of peripheral delivery of human antibodies. 
Peter Davies (Feinstein Institute for Medical Research, NY) has developed very critical monoclonal antibodies to Tau, which is a major player in neurofibrillary tangles of Alzheimer’s disease, and the accumulating protein in hereditary and injury-induced dementias. “Treatment of Neuronal Pathology with Monoclonal Antibodies” discusses moving these valuable diagnostic and research tools into the therapeutic realm. The final talk, by Eliezer Masliah (National Institutes of Aging, NIH), is “Combinatorial Immunotherapeutic Approaches for Synucleinopathies of the Aging Population.” This innovative approach harnesses both adaptive and innate immune processes that will be critical for dealing with Parkinsons and several other aging diseases that accumulate alpha-synuclein.

Interested in attending the meeting? Society members can save 15% on the registration fee!
Not a member? Please join!
Membership is free for students and employees of the Society’s corporate sponsors.

Filed Under: Antibody discovery, Meetings, The Antibody Society Tagged With: antibody therapeutics, neurodegeneration

Share this post

  • LinkedIn

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III Starts Tomorrow! May 20, 2025
  • Exciting news – The AIRR Community is turning 10! 🎂 May 8, 2025
  • The Antibody Society (TAbS): Win a FREE Attendance Pass to AET Basel & Present A Poster: Call For Abstracts! March 26, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals